NCT03030287View on ClinicalTrials.gov

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Cancer OvariesCancer PeritonealCancer, Fallopian Tube
Interventions
DRUG

OMP-305B83

intravenous (in the vein) infusion

DRUG

Paclitaxel

administered intravenously

Trial Locations (7)

19104

The University of Pennsylvania Health System, Philadelphia

28204

Levine Cancer Institute, Charlotte

33612

H. Lee Moffitt Cancer Center & Research Institute, Inc. (Moffitt Cancer Center), Tampa

37203

Tennessee Oncology, PLLC, Nashville

73104

Stephenson Cancer Center, Oklahoma City

77030

The University of Texas, MD Anderson Cancer Center, Houston

80045

University of Colorado, Anschutz Medical Campus, Aurora

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY

NCT03030287 - A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter